Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
MedPage Today on MSN
FDA expands approval of chemo-free bladder cancer combo in curative setting
Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility ...
The Food and Drug Administration approved a combination treatment by Merck & Co., Pfizer, and Astellas Pharma for a hard-to-treat form of bladder cancer. The agency greenlit Merck's Keytruda and its ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
A groundbreaking targeted treatment for the most common type of bladder cancer has been approved for use by the NHS, offering new hope to hundreds of patients. The National Institute of Health and ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...
It’s important to know what kinds of treatments are available for bladder cancer and understand that having a “tailored” treatment is important for patients, experts said. There are so many types of ...
A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology. High-risk non–muscle-invasive bladder ...
The National Institute for Health and Care Excellence (NICE) published draft guidance recommending avelumab (Bavencio, Merck Serono) for the treatment of certain forms of bladder cancer. Adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results